Expanded access to telisotuzumab adizutecan
Treatments studied
Part of Cancer clinical trials.
This trial provides early access to a medication called telisotuzumab adizutecan for people who have run out of other treatment choices. It's for those who cannot join a regular clinical trial but might benefit from this experimental drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have no other standard treatment options available that your doctor recommends.
- You must not qualify for any ongoing clinical trials for your condition.
- You need a doctor who is willing to request this drug for you on a compassionate-use basis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called telisotuzumab adizutecan against the usual treatments for people with a type of lung cancer that has spread and has not responded to previous therapy. It may be an option if your cancer has a specific marker and you have not had certain other conditions.
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
This trial is studying a new drug, telisotuzumab adizutecan, in combination with other treatments for advanced bile duct or pancreatic cancers. The goal is to see if the combination helps control the cancer. It's designed for people who are relatively active and can do their daily tasks.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.